ReviewBiomaterials translational2026
Transforming therapeutics through biomaterials: A comprehensive insight into biomaterials' role in effective drug delivery and healthcare advancement.
Review in Biomaterials translational, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomaterials are engineered substances designed to interact with biological systems for therapeutic or diagnostic purposes. Their inherent properties-including biocompatibility, biodegradability, and structural versatility-have driven major advancements in drug delivery technologies. The global biomaterials market size was estimated at USD 178.0 billion in 2023 and is projected to grow at a compound annual growth rate of 15.6% from 2024 to 2030. The growing incidence of musculoskeletal and chronic skeletal disorders is expected to drive demand for biomaterial-based implants, thereby contributing to market expansion. This review critically examines biomaterials, focusing on their classification into biobased, biodegradable, and biocompatible categories and analyzes their physicochemical properties and functional benefits. It highlights their applications in oncology, cardiovascular therapy, neurodegenerative diseases, and vaccination. Key challenges-including immunogenicity, cytotoxicity, and manufacturing complexities-are discussed, emphasizing the need for rigorous evaluation and adaptive regulatory frameworks. The review also explores recent advances in smart biomaterials for precision drug delivery, underscoring their potential to revolutionize personalized medicine through targeted, efficient, and patient-specific therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.